Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection

J Am Acad Dermatol. 2023 May;88(5):1125-1127. doi: 10.1016/j.jaad.2022.05.005. Epub 2022 May 10.

¹ Department of Dermatology, Columbia University Irving Medical Center, New York, New York.
² Department of Dermatology, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
³ Department of Dermatology, Columbia University Irving Medical Center, New York, New York; Medical Scientist Training Program, Columbia University, New York, New York.
⁴ Department of Biostatistics, Columbia University, New York, New York.
⁵ Department of Dermatology, Columbia University Irving Medical Center, New York, New York. Electronic address: [email protected].

No abstract available

Keywords: COVID-19 infection; JAK inhibitor; SARS-CoV-2; alopecia areata; tofacitinib.

MeSH terms